Sahajanand Medical Technologies has raised Rs 140.06 crore from anchor investors, including domestic mutual funds. The company's Rs 475.48 crore initial public offering (IPO) will open for subscription on October 15, with a price band set at Rs 327–344 per share.
Sahajanand Medical Technologies Limited (SMT) has finalized its anchor investor round, securing Rs 140.06 crore just ahead of its upcoming public issue. The company, which focuses on cardiovascular devices, attracted interest from eight institutional investors, including major domestic mutual funds such as Nippon Life India, DSP Mutual Fund, WhiteOak Capital, Invesco India, and UTI AMC. This anchor allotment was priced at the upper end of the Rs 327–344 price band. The full public offering is scheduled to open for subscription on October 15 and will close on October 19, 2026.
IPO Structure and Offer for Sale
The entire Rs 475.48 crore public issue is an offer-for-sale (OFS). This means that all the money raised from the IPO will go directly to the existing selling shareholders, which include promoters and institutional backers like Samara Capital and Morgan Stanley-backed NHPEA Sparkle Holding B.V. The company itself will not receive any of the proceeds to fund its business, expansion, or debt reduction. Potential investors should note that since no fresh capital is being raised, the company’s cash flow and balance sheet will not see any immediate impact from the listing process.
Business and Financial Context
Mumbai-based Sahajanand Medical Technologies operates in the specialized space of Class III and Class C/D medical devices. Its product range includes coronary stents, balloons, and structural heart solutions like transcatheter aortic valve implantation (TAVI) devices. The company has a significant global footprint, with operations spanning 77 countries. For the financial year 2026, the company reported revenue of approximately Rs 1,210.50 crore and a profit after tax of Rs 69.08 crore.
Risks Including Product Concentration and Price Controls
Investors evaluating the IPO should consider several operational and regulatory risks. A major factor is the company's heavy dependence on its flagship product, 'Supraflex Cruz,' which accounted for 37.17% of total revenue in FY26. Any slowdown in demand or regulatory issues specifically affecting this product could have a disproportionate impact on the company’s performance.
Furthermore, the medical device sector in India faces significant regulatory pressure. The government’s price ceilings on coronary stents directly impact profit margins. Additionally, the business model relies heavily on imported raw materials, which accounted for over 77% of purchases in the last financial year, exposing the company to currency fluctuations and supply chain risks. The company also maintains a long working capital cycle of 138 days, which can pressure cash flow. With the IPO priced at a trailing P/E of approximately 53x, market participants will likely monitor whether the company’s growth trajectory justifies this valuation.
The shares are expected to list on the NSE and BSE on October 23, 2026. Future monitorables for shareholders include the company's ability to diversify its product portfolio beyond the flagship stent and manage its working capital requirements effectively amid stiff competition in the medical device sector.